Autistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome
Recruiting · NCT06877715 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Toulouse
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Prader-Willi Syndrome (PWS) is a rare neurodevelopmental disorder stemming from genetic damage in the 15q11-q13 region, leading to hypothalamic dysfunction. Individuals with PWS often exhibit social interaction challenges, intellectual deficits, significant eating disorders, mood disturbances, and sensory-related autistic features. Although PWS is recognized by DSM-5 as a genetic cause of Autism Spectrum Disorder (ASD), ASD diagnosis in PWS remains rare in France. The CASSPER study aims to investigate the distinct autistic and sensory profiles in children with PWS, also analyzing the potential impact of early oxytocin treatment on these manifestations, in line with recommendations for early and tailored intervention.
Who can take part
Inclusion criteria
- Child with genetically confirmed PWS and identification of genetic subtype;
- Child aged between 3 and 16 years;
- Hospitalisation or multidisciplinary consultation planned for the child's routine follow-up at one of the investigating centres;
- No parental/legal guardian objection.
Exclusion criteria
- Change in psychotropic treatment (start, change in dose or discontinuation) in the past 3 months;
- Inability to provide clear information to parents/legal guardian;
- Not covered by social security.
Where it is running
1 location listed.
- Children Hospital - Toulouse, France